Article citationsMore>>
S. E. Pinder, C. Duggan, I. O. Ellis, J. Cuzick, J. F. Forbes, H. Bishop, I. S. Fentiman, W. D. George and UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma in Situ (DCIS) Working Party, “A New Pathological System for Grading DCIS with Improved Prediction of Local Recurrence: Results from the UKCCCR/ANZ DCIS Trial,” British Journal of Cancer, Vol. 103, No. 1, 2010, pp. 94-100.
http://dx.doi.org/10.1038/sj.bjc.6605718
has been cited by the following article:
-
TITLE:
Current Treatment of DCIS
AUTHORS:
Christina Choy, Kefah Mokbel
KEYWORDS:
Early Breast Cancer; DCIS; Breast Cancer Diagnosis and Treatment
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.2,
February
12,
2014
ABSTRACT:
Abstract: Ductal
carcinoma in-situ DCIS is a
heterogeneous entity in breast neoplasm with unpredictable biological behavior.
This poses challenge in the management of DCIS. Various trials on DCIS have
shown good outcome with integral treatment of adequate surgery, radiotherapy
and hormonal therapy. Identification of subgroup of DCIS for radiotherapy and
hormonal therapy could improve recurrence rate, contralateral tumours incidence
and perhaps overall survival. Various risk score calculations could help to
direct radiotherapy and hormonal treatment verses surgery alone and to avoid
over treatment. Oncotype DX
assay could be a new way of risk calculation to direct types of DCIS treatment.
The recent increased use of MRI could increase the detection of DCIS and a more
accurate extent of disease estimation. This article is a summary of major
literatures and major trials result for DCIS.
Related Articles:
-
Rodrigo Arrangoiz, Fernando Cordera, Eduardo Moreno, Enrique Luque-de-Leon, Manuel Muñoz
-
Jai Dev Chandel, Nand Lal Singh
-
Pierpaolo Perrucci
-
Anqi Ding, Ting Zhang
-
Fokam Tagne Achille Bernard, Marie Claire Komtangi, Julius Awah Ndukum, Fossi Josue, Djamen Tchantchou Chamberlin